{
    "laboratory_examinations": [
        {
            "procedure_name": "Bilirubin Level",
            "date": "Not specified",
            "findings": "314 mmol/L (reference range, 0–20 mmol/L)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Alanine Aminotransferase Level",
            "date": "Not specified",
            "findings": "87.5 mkat/L (reference range, 0–0.8 mkat/L)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Prothrombin Time",
            "date": "Not specified",
            "findings": "21.3 s (reference range, 10.9–15.3 s)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "International Normalized Ratio",
            "date": "Not specified",
            "findings": "1.85 (reference range, 0.80–1.20)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "D-dimer Level",
            "date": "Not specified",
            "findings": "1380.0 ng/mL (reference range, 0–250 ng/mL)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Antithrombin III Level",
            "date": "Not specified",
            "findings": "31% (reference range, 81%–130%)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Hepatitis B Surface Antigen Test",
            "date": "1 month after lamivudine therapy started",
            "findings": "Undetectable",
            "changes_over_time": "Biochemical and coagulation test results were normal 5 weeks after initial therapy."
        }
    ]
}